Product datasheet

Anti-Androgen Receptor antibody [EPR1535(2)]
ab133273

Overview

Product name
Anti-Androgen Receptor antibody [EPR1535(2)]

Description
Rabbit monoclonal [EPR1535(2)] to Androgen Receptor

Host species
Rabbit

Tested applications
Suitable for: WB, IHC-P, ICC/IF

Species reactivity
Reacts with: Mouse, Rat, Human

Immunogen
Synthetic peptide within Human Androgen Receptor aa 1-100 (N terminal). The exact sequence is proprietary.
Database link: P10275
(Peptide available as ab191380)

Positive control
WB: T47-D, LnCaP and 22Rv1 cell lysates; Rat and mouse prostate lysates. IHC-P: Human prostate, prostatic adenocarcinoma, prostatic hyperplasia tissues; Rat and mouse testis tissues; Breast carcinoma and prostatic carcinoma T3 tissues. ICC/IF: MCF7 cells;EP156T-AR, 957E/4TERT-AR and LNCaP cells.

General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free production
For more information see here.

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

Properties
Form  Liquid
Storage buffer  pH: 7.40
Preservative: 0.01% Sodium azide
 Constituents: 40% Glycerol, 0.05% BSA, 59% PBS
Purity  Protein A purified
Clonality  Monoclonal
Clone number  EPR1535(2)
Isotype  IgG

Applications

Our Abpromise guarantee covers the use of ab133273 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

<table>
<thead>
<tr>
<th>Application</th>
<th>Abreviews</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>WB</td>
<td>1/2000. Predicted molecular weight: 98 kDa. Can be blocked with Androgen Receptor peptide (ab191380). For unpurified use at 1:1000</td>
<td>For Lysate preparation protocol, please refer to the protocol book in the protocol section and/or here (downloadable copy).</td>
</tr>
<tr>
<td>IHC-P</td>
<td>1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. See IHC antigen retrieval protocols. For unpurified use at 1/100-1/250</td>
<td></td>
</tr>
<tr>
<td>ICC/IF</td>
<td>1/100 - 1/250</td>
<td></td>
</tr>
</tbody>
</table>

Target

Function  Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3. Isoform 3 and isoform 4 lack the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.

Tissue specificity  Isoform 2 is mainly expressed in heart and skeletal muscle (PubMed:15634333). Isoform 3 is expressed by basal and stromal cells of prostate (at protein level) (PubMed:19244107).

Involvement in disease  Androgen insensitivity syndrome
Spinal and bulbar muscular atrophy X-linked 1
Defects in AR may play a role in metastatic prostate cancer. The mutated receptor stimulates prostate growth and metastases development despite of androgen ablation. This treatment can reduce primary and metastatic lesions probably by inducing apoptosis of tumor cells when they
express the wild-type receptor.
Androgen insensitivity, partial

Sequence similarities
Belongs to the nuclear hormone receptor family. NR3 subfamily.
Contains 1 nuclear receptor DNA-binding domain.

Domain
Composed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain. In the presence of bound steroid the ligand-binding domain interacts with the N-terminal modulating domain, and thereby activates AR transcription factor activity. Agonist binding is required for dimerization and binding to target DNA. The transcription factor activity of the complex formed by ligand-activated AR and DNA is modulated by interactions with coactivator and corepressor proteins. Interaction with RANBP9 is mediated by both the N-terminal domain and the DNA-binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA-binding domain.

Post-translational modifications
Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. Phosphorylation by TNK2 enhances the DNA-binding and transcriptional activity and may be responsible for androgen-independent progression of prostate cancer. Phosphorylation at Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. Phosphorylation by PAK6 leads to AR-mediated transcription inhibition. Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.

Cellular localization
Nucleus. Cytoplasm. Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1.

Form
There are 2 isoforms produced by alternative splicing. Isoform 1 is also known as: AR-B; isoform 2 is known as AR-A or variant AR45.

Images

**All lanes**: Anti-Androgen Receptor antibody [EPR1535(2)] (ab133273) at 1/1000 dilution

**Lane 1**: Mouse testis lysate
**Lane 2**: Rat testis lysate
**Lane 3**: Mouse liver lysate
**Lane 4**: Rat liver lysate
Lysates/proteins at 20 µg per lane.

**Secondary**

**All lanes**: Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
**Predicted band size:** 98 kDa  
**Observed band size:** 110 kDa  
*why is the actual band size different from the predicted?*

**Exposure time:** 20 seconds  

**Blocking/Diluting buffer:** 5% NFDM/TBST  
**Loading Control:** Rabbit monoclonal [EPR16891] to GAPDH (ab181602)

Anti-Androgen Receptor antibody [EPR1535(2)] (ab133273) at 1/5000 dilution (purified) + Mouse prostate lysates at 15 µg

**Secondary**  
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution  

**Predicted band size:** 98 kDa

Blocking and diluting buffer: 5% NFDM/TBST

Texas red (Tx-Red) indirect immunofluorescent detection of Androgen Receptor using ab133273 in (A) EP156T-AR, (B) 957E/hTERT-AR and (C) LNCaP cells. The cells were treated with ± 1 nM R1881 for 24 hours.
Formalin-fixed, paraffin-embedded tissues labeling Androgen Receptor with ab133273. Left: Tumor from orthotopic injection of PTEN KD/TE cells. Right: Human prostate cancer tissue.

From Figure 3 of Shao et al


Reproduced under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0).

Immunocytochemistry/ Immunofluorescence analysis of MCF7 (Human breast adenocarcinoma epithelial cell) cells labeling Androgen receptor with purified ab133273 at 1:100 dilution (1.3μg/ml). Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with Ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) 1:200 (2.5 μg/ml). ab150077 Goat anti rabbit IgG(Alexa Fluor® 488) was used as the secondary antibody at 1:1000 dilution. DAPI nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.

Immunohistochemical analysis of paraffin-embedded human prostatic adenocarcinoma tissue labelling Androgen Receptor using unpurified ab133273 at 1/100 dilution.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Western blot - Anti-Androgen Receptor antibody [EPR1535(2)] (ab133273)

All lanes: Anti-Androgen Receptor antibody [EPR1535(2)] (ab133273) at 1/20000 dilution

Lane 1: LNCaP (Human prostate carcinoma epithelial cell) whole cell lysates prepared in RIPA lysis method

Lane 2: LNCaP (Human prostate carcinoma epithelial cell) whole cell lysates prepared in 1%SDS Hot lysis method

Lane 3: 22Rv1 (Human prostate carcinoma epithelial cell) whole cell lysates prepared in RIPA lysis method

Lane 4: 22Rv1 (Human prostate carcinoma epithelial cell) whole cell lysates prepared in 1%SDS Hot lysis method

Lysates/proteins at 1/15 dilution per lane.

Secondary
All lanes: Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution (Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated)

Predicted band size: 98 kDa

Observed band size: 120 kDa

why is the actual band size different from the predicted?

Exposure time: 10 seconds

Blocking/Diluting buffer - 5% NFDM/TBST

The androgen receptor variant band detected in 22RV1 cells is reported by PMID: 22315407.

We recommend you to try both RIPA and 1%SDS Hot lysis preparation methods to get desired bands.
Immunocytochemistry/ Immunofluorescence - Anti-Androgen Receptor antibody [EPR1535(2)] (ab133273)

Immunofluorescent staining of LnCAP cells labelling Androgen Receptor using unpurified ab133273, at 1/100 dilution

Western blot - Anti-Androgen Receptor antibody [EPR1535(2)] (ab133273)

All lanes: Anti-Androgen Receptor antibody [EPR1535(2)] (ab133273) at 1/5000 dilution (purified)

Lane 1: LNCaP (Human prostate carcinoma epithelial cell) whole cell lysates
Lane 2: Rat prostate lysates

Lysates/proteins at 20 µg per lane.

Secondary
All lanes: Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/2000 dilution

Predicted band size: 98 kDa

Blocking and diluting buffer: 5% NFDM/TBST
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of rat testis tissue sections labeling Androgen Receptor with Purified ab133273 at 1:500 dilution (0.25 μg/ml). Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). Tissue was counterstained with Hematoxylin. ImmunoHistoProbe one step HRP Polymer (ready to use) secondary antibody was used at 1:0 dilution. PBS instead of the primary antibody was used as the negative control.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of mouse testis tissue sections labeling Androgen Receptor with Purified ab133273 at 1:500 dilution (0.25 μg/ml). Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). Tissue was counterstained with Hematoxylin. ImmunoHistoProbe one step HRP Polymer (ready to use) secondary antibody was used at 1:0 dilution. PBS instead of the primary antibody was used as the negative control.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human prostatic hyperplasia tissue sections labeling Androgen Receptor with Purified ab133273 at 1:500 dilution (0.25 μg/ml). Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). Tissue was counterstained with Hematoxylin. ImmunohistoProbe one step HRP Polymer (ready to use) secondary antibody was used at 1:0 dilution. PBS instead of the primary antibody was used as the negative control.

Western blot - Anti-Androgen Receptor antibody [EPR1535(2)] (ab133273)

Anti-Androgen Receptor antibody [EPR1535(2)] (ab133273) at 1/1000 dilution (unpurified) + LNCaP (Human prostate carcinoma epithelial cell) at 10 μg

Secondary
Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

Predicted band size: 98 kDa
Observed band size: 110 kDa why is the actual band size different from the predicted?

Exposure time: 3 seconds

Blocking/Diluting buffer 5% NFDM/TBST
Immunohistochemical analysis of paraffin-embedded human prostate tissue labelling Androgen Receptor using unpurified ab133273, at 1/100 dilution.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Unpurified ab133273 showing positive staining in Breast carcinoma tissue.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Unpurified ab133273 showing negative staining in Normal brain tissue.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Unpurified ab133273 showing negative staining in Normal tonsil tissue.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Unpurified ab133273 showing positive staining in Endometrial carcinoma tissue.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Unpurified ab133273 showing negative staining in Normal breast tissue.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Androgen Receptor antibody [EPR1535(2)] (ab133273)

Unpurified **ab133273** showing negative staining in Normal colon tissue.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Androgen Receptor antibody [EPR1535(2)] (ab133273)

Unpurified **ab133273** showing negative staining in Ovarian carcinoma tissue.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Androgen Receptor antibody [EPR1535(2)] (ab133273)

Unpurified **ab133273** showing negative staining in Colonic adenocarcinoma tissue.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Unpurified ab133273 showing negative staining in Normal liver tissue.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Unpurified ab133273 showing positive staining in Prostatic carcinoma T3 tissue.

Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit https://www.abcam.com/abpromise or contact our technical team.
Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors